Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated liposomal doxorubicin versus capecitabine in older patients with metastatic breast cancer
NL-OMON25134Phase 3Not yet recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Feb 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Pegylated liposomal doxorubicin with Capecitabine (2 arms). Primary endpoint: Progression-free survival / time to progression. Planned start Feb 2007; status: not yet recruiting.
02
Drugs
doxorubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON25134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25134.